Polar Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Polar Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-588,062	Closed	-$4.5M	–	305
2020 Q1	$4.5M	Sell	588,062 -70,600	-11%	-$953K	0.05%	206
2019 Q4	$11.7M	Sell	658,662 -745,073	-53%	-$9.72M	0.1%	188
2019 Q3	$16.3M	Buy	1,403,735 +16,235	+1%	+$262K	0.15%	159
2019 Q2	$30.7M	Buy	1,387,500 +238,300	+21%	+$5.59M	0.27%	120
2019 Q1	$32.9M	Buy	1,149,200 +1,070,300	+1,357%	+$23.2M	0.31%	110
2018 Q4	$1.56M	Buy	+78,900	New	+$1.59M	0.02%	237

Other funds holding KALV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Polar Capital's KALV Position: Q2 2020 in Review

Polar Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2020, closing a stake of 588,062 shares — an estimated $4.5M sold.

Polar Capital first reported a position in KALV in Q4 2018 and held it in 6 quarters. The position peaked at $32.9M in Q1 2019. 72 funds tracked by Wall St. Rank hold KALV as of Q2 2020.

Polar Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Polar Capital sold 588,062 KalVista Pharmaceuticals shares in Q2 2020, an estimated $4.5M.
Polar Capital first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Polar Capital's KalVista Pharmaceuticals position peaked at $32.9M in Q1 2019.
72 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2020.

Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.